Article
Rare histologic transformation of a CTNNB1 (β-catenin) mutated prostate cancer with aggressive clinical course.
Diagnostic pathology - 21 Jun 2024
Akhoundova Dilara, Fischer Stefanie, Triscott Joanna, Lehner Marika, Thienger Phillip, Maletti Sina, Jacquet Muriel, Lubis Dinda S H, Bubendorf Lukas, Jochum Wolfram, Rubin Mark A
Abstract excerpt
BACKGROUND: Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) genomic alterations are rare in prostate cancer (PCa). Gain-of-function mutations lead to overexpression of β-catenin, with consequent hyperactivation of the Wnt/β-catenin signaling pathway, implicated in PCa progression and treatment resistance. To date, successful targeted treatment options for Wnt/β-catenin - driven PCa are lacking. METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.